Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer

Phase 3CompletedNCT00192712

Rambam Health Care Campus20 enrolled

Overview

The study hypothesis is that chemoradiation based on 2 drugs will improve local control and long-term survival in patients with locally advanced pancreatic cancer. That is why gemcitabine and irinotecan are combined in an induction phase of 2 months and then this IrinoGem combination is given for 3 more cycles, in reduced doses,concurently with irradiation.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pancreatic Cancer

Interventions

irinotecan, gemcitabineDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * locally advanced pancreatic cancer * performance status 0-2 * normal blood count and chemistry * no previous chemotherapy or radiotherapy Exclusion Criteria: * serious concurrent systemic disease

Locations (1)

Department of Oncology, Rambam Medical Center

Haifa, Israel

Outcomes

Primary Outcomes

time to treatment failure

Secondary Outcomes

response rate, survival, toxicity

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.